Results 41 to 50 of about 18,506 (177)
Binding of busulfan to plasma proteins and blood cells
, 1984 The reversible and non-reversible binding of busulfan to plasma proteins and to blood cells has been evaluated in man. The reversible binding to plasma proteins was insignificant in both healthy subjects and in patients with chronic myelocytic leukaemia.
Hans Ehrsson, Moustapha Hassan
core +1 more source
American Journal of Hematology, EarlyView.ABSTRACT Posttransplant cyclophosphamide (PTCy) to prevent graft‐versus‐host disease (GVHD) improves outcomes in recipients of HLA mismatched unrelated donor (MMUD) allogeneic hematopoietic cell transplantation (allo HCT). Outcomes of MMUD HCT using PTCy in patients requiring reduced intensity or non‐myeloablative conditioning (RIC/NMA) are not well ...
Brian C. Shaffer +38 more
wiley +1 more source
Performance of Busulfan Dosing Guidelines for Pediatric Hematopoietic Stem Cell Transplant Conditioning [PDF]
, 2015 Achievement of a busulfan area-under-the-concentration versus time curve (AUC) of 900 to 1500 μM·min is associated with improved hematopoietic stem cell transplant (HSCT) outcomes. Multiple pediatric busulfan dosing guidelines aim to achieve this target.
Zao, Jamie H. +7 more
core +1 more source
, 2022 Aims: The aims of the study were to 1) establish a population pharmacokinetic (Pop-PK) model for busulfan in Chinese pediatric patients undergoing hematopoietic stem cell transplantation (HSCT) and then estimate busulfan exposure and 2) explore the ...
Yiduo Ding (12879719) +17 more
core +1 more source
Food Safety and Health, EarlyView.Fenugreek and stevia extracts protect against dexamethasone‐induced testicular damage in male rats by enhancing antioxidant defenses, improving sperm quality, and restoring hormonal balance, highlighting their potential as natural therapeutics for preventing corticosteroid‐induced reproductive toxicity.
Mosab Gad +3 more
wiley +1 more source
A novel drug interaction between busulfan and blinatumomab
, 2017 Busulfan is an alkylating agent used in pre-transplant conditioning for patients undergoing hematopoietic stem cell transplantation. Several factors contribute to variations in busulfan drug disposition including bioavailability, age, liver function ...
Jonathan Lee +6 more
core +1 more source
PLoS ONE, 2018 In this study we utilized a large animal model to identify a dose of intravenous busulfan that can cause reversible myelosuppression. Nine baboons (Papio anubis) were treated with IV busulfan at 6.4 (Group A), 8 (Group B), or 9.6 mg/kg (Group C ...
Nadim Mahmud +10 more
doaj +1 more source
Stability of Busulfan in Frozen Plasma and Whole Blood Samples
, 2001 Busulfan is widely used as a component of myeloablative conditioning therapy for bone marrow transplantation (1)(2)(3)(4)(5). Busulfan is most often used at a fixed total dose of 16 mg/kg. Wide interindividual variation in the bioavailability of busulfan
Chandy, Mammen +2 more
core +1 more source
Diagnosis and Management of Prenatal Hereditary Pyropoikilocytosis
Prenatal Diagnosis, EarlyView.ABSTRACT Hereditary pyropoikilocytosis (HPP) is a severe hemolytic anemia caused by variants in SPTA1, SPTB, and EPB41. These weaken horizontal interactions in the erythrocyte cytoskeleton, causing membrane fragmentation and splenic sequestration. It will readily cause fetal anemia and often hydrops fetalis. Prenatal diagnosis requires first ruling out
Connor Hartzell +6 more
wiley +1 more source
Pharmacometabonomic Prediction of Busulfan Clearance in Hematopoietic Cell Transplant Recipients
, 2016 Intravenous (IV) busulfan doses are often personalized to a concentration at steady state (Css) using the patient’s clearance, which is estimated with therapeutic drug monitoring. We sought to identify biomarkers of IV busulfan clearance using a targeted
Sandi L. Navarro (2884988) +4 more
core +1 more source